Knockout of angiotensin 1-7 receptor mas worsens the course of two-kidney, one-clip goldblatt hypertension: Roles of nitric oxide deficiency and enhanced vascular responsiveness to angiotensin II

Kidney and Blood Pressure Research

Volumn 33, Issue 6, 2010, Pages 476-488

  Rakuan, Dan ^a   Bürgelová, Marcela ^a   Vanková, Ivana ^a,b   Vaourková, Zdeka ^a,b   Husková, Zuzana ^a,b   Karoupková, Petra ^a   Mrázová, Iveta ^a   Opoenský, Martin ^a   Kramer, Herbert J ^c   Netuka, Ivan ^b   Malý, Jan ^a   Alenina, Natalia ^d   Bader, Michael ^d   Santos, Robson A S ^e   Červenka, Ludk ^a,b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF BONN   (Germany)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Mas receptor knockout mice; Nitric oxide deficiency; Two kidney, one clip Goldblatt hypertension

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR MAS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ENZYME INHIBITION; HORMONE ACTION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DISEASE PROGRESSION; HYPERTENSION, RENOVASCULAR; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SURGICAL INSTRUMENTS; VASOMOTOR SYSTEM;

EID: 78149317303     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320689     Document Type: Article

References (43)

1. Navar LG, Zou L, Von Thun A, Wang CT, Imig JD, Mitchell KD: Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 1998; 13: 170-176.
2. Kobori H, Nangaku M, Navar LG, Nishiyama A: The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287.
3. Cervenka L, Wang CT, Mitchell KD, Navar LG: Proximal tubular angiotensin II levels and renal functional responses to AT 1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Hypertension 1999; 33: 102-107. (Pubitemid 29061849)
4. Èervenka L, Vanìèková I, Husková Z, Vaòourková Z, Erbanová M, Thumová M, Škaroupková P, Opoèenský M, Malý J, Èertíková Chábová V, Tesaø V, Bürgelová M, Viklický O, Teplan V, Želízko M, Kramer HJ, Navar LG: Pivotal role of AT 1A receptors in the development of two-kidney, one-clip hypertension: study in AT 1A receptor knockout mice. J Hypertens 2008; 26: 1379-1389.
5. Walkowska A, Škaroupková P, Husková Z, Vaòourková Z, Èertíková Chábová V, Tesaø V, Kramer HJ, Falck JR, Imig JD, Kompanovska-Jezierska E, Sadowski J, Èervenka L: Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. J Hypertens 2010; 28: 582-593.
6. Iusuf D, Henning RH, van Gilst WH, Roks AJ: Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 2008; 585: 303-312.
7. Santos RAS, Ferrerira AJ, Simoes e Silva AC: Recent advances in the angiotensin-converting enzyme2-angiotensin(1-7)-Mas axis. Exp Physiol 2008; 93: 519-527.
8. Ingelfinger JR: Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 2009; 18: 79-84.
9. Santos RAS, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walter S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemons VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T: Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263.
10. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walter S, Sexton PM, Gembardt F, Kellet E, Martini L, Vanderheyden P, Walther T: G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005; 111: 1806-1813.
11. Carvalho MBL, Duarte FV, Faria-Silva R, Fauler B, da Mata Machado LT, de Paula RD, Campagnole-Santos MJ, Santos RA: Evidence for Mas-mediated bradykinin potentiation by the angiotensin-(1-7) nonpeptide mimic AVE 0991 in normotensive rats. Hypertension 2007; 50: 762-767.
12. Xu P, Costa-Gocalves A, Todiras M, Rabelo LA, Sampaio WO, Moura MM, Santos SS, Luft FC, Bader M, Gross V, Alenina N, Santos RA: Endothelial dysfunction and elevated blood pressure in Mas gene-deleted mice. Hypertension 2008; 51: 574-580.
13. Bürgelová M, Kramer HJ, Teplan V, Thumová M, Cervenka L: Effects of angiotensin-( 1-7) blockade on renal function in rats with enhanced intrarenal ANG II activity. Kidney Int 2005; 67: 1453-1461.
14. Bürgelová M, Vaòourková Z, Thumová M, Dvoøák P, Opoèenský M, Kramer HJ, Dvoøák P, Èervenka L: Impairment of the angiotensin-convertin enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension. J Hypertens 2009; 27: 1988-2000.
15. Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M: Genetically altered animal models for Mas and angiotensin-(1-7). Exp Physiol 2008; 93: 528-537.
16. Bürgelová M, Kramer HJ, Teplan V, Velièková G, Vítko S, Heller J, Malý J, Èervenka L: Intrarenal infusion of angiotensin-(1-7) modulates renal functional responses to exogenous angiotensin II in the rat. Kidney Blood Press Res 2002; 25: 202-210.
17. Heller J, Kramer HJ, Malý J, Èervenka L, Horáèek V: Effect of intrarenal infusion of angiotensin-(1-7) in the dog. Kidney Blood Press Res 2000; 23: 89-94.
18. Navar LG, Ichihara A, Chin SY, Imig JD: Nitric oxide-angiotensin II interactions in angiotensin II-dependent hypertension. Acta Physiol Scand 2000; 168: 139-147.
19. Mitchell KD, Botros FT, Navar LG: Intrarenal renin-angiotensin system and counteracting protective mechanisms in angiotensin II-dependent hypertension. Acta Physiol Hung 2007; 94: 31-48.
20. Faria-Silva R, Duarte FV, Santos RAS: Shortterm angiotensin-(1-7) receptor Mas stimulation improves endothelial function in normotensive rats. Hypertension 2005; 46: 948-952.
21. Sampai WO, Santos RAS, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM: Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007; 49: 185-192.
22. Èervenka L, Horáèek V, Vanìè ková I, Hubáèek JA, Oliverio MI, Coffman TM, Navar LG: Essential role of AT 1A receptor in the development of 2K1C hypertension. Hypertension 2002; 40: 735-741.
23. Sampaio WO, Castro CH, Santos RAS, Schiffrin EL, Touyz RM: Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007; 50: 1093-1098.
24. Ortiz PA, Garvin JL: Superoxide stimulates NaCl absorption by the thick ascending limb. Am J Physiol 2002; 283:F957-F962.
25. Kopkan L, Husková Z, Vanourková Z, Thumová M, Skaroupková P, Cervenka L, Majid DS: Superoxide and its interaction with nitric oxide modulates renal function in prehypertensive Ren-2 transgenic rats. J Hypertens 2007; 25: 2257-2265.
26. Elmarakby AA, Williams JM, Imig JD, Pollock JS, Pollock DM: Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. Vascul Pharmacol 2007; 46: 144-151.
27. Kopkan L, Husková Z, Vaòourková Z, Thumová M, Šakroupková P, Malý J, Kramer HJ, Dvoøák P, Èervenka L: Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. Vascul Pharmacol 2009; 51: 175-181.
28. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL: Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 2004; 22: 535-542.
29. Husková Z, Kramer HJ, Thumová M, Vaòourková Z, Bürgelová M, Teplan V, Èervenka L: Effects of anaesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press Res 2006; 29: 74-83.
30. Fox J, Guan S, Hymel AA, Navar LG: Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol 1992; 262:F902-F909.
31. Kopkan L, Kramer HJ, Huskova Z, Vaòourková Z, Škaroupková P, Thumová M, Èervenka L: The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J Hypertens 2005; 23: 1531-1539.
32. Vaòourková Z, Kramer HJ, Husková Z, Vanìèková I, Opoèenský O, Èertíková Chábová V, Tesaø V, Thumová M, Dohnalová M, Mullins JJ, Èervenka L: AT 1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens 2006; 24: 2465-2472.
33. Erbanová M, Thumová M, Husková Z, Vanìèková I, Vaòourková Z, Mullins JJ, Kramer HJ, Bürgelová M, Rakušan D, Èervenka L: Impairment of the autoregulation of renal hemodynamics and the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens 2009; 27: 575-586.
34. Èertíková Chábová V, Kramer HJ, Vanìèková I, Vernerová Z, Eis V, Tesaø V, Škaroupková P, Thumová M, Schejbalová S, Husková Z, Vaòourková Z, Kolský A, Imig J, Èervenka L: Effects of chronic cytochrome P-450 inhibition on the course of hypertension and endorgan damage in Ren-2 transgenic rats. Vascul Pharmacol 2007; 47: 145-159.
35. Jacinto SM, Mullins JJ, Mitchell KD: Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats. Am J Physiol 1999; 276:F315-F322.
36. Dilauro M, Burns KD: Angiotensin-(1-7) and its effects in the kidney. ScientificWorld-Journal 2009; 9: 522-535.
37. Reckelhoff JF, Romero JC: Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol 2003; 284:R893-R912.
38. Wilcox CS: Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol 2005; 289:R913-R935.
39. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM: Altered blood pressure responses and cardiac phenotype in ACE2-null mice. J Clin Invest 2006; 116: 2218-2225.
40. Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM, Battle D: Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2. Prevention of angiotensin II-dependent hypertension. Hypertension 2010; 55: 90-98.
41. Walther T, Wessel N, Kang N, Sander A, Tschope C, Malberg H, Bader M, Voss A: Altered heart rate and blood pressure variability in mice lacking the Mas protooncogene. Braz J Med Biol Res 2000; 33: 1-9.
42. Deschepper CF, Olson JL, Otis M, Gallo-Payet N: Characterization of blood pressure and morphological traits in cardiovascularrelated organs in 13 different inbred mouse strains. J Appl Physiol 2004; 97: 369-376.
43. Gurley SB, Coffman TM: Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. Exp Physiol 2008; 93: 538-542.